logo-loader
RNS
SkinBioTherapeutics PLC

Appointment of Interim CFO

RNS Number : 8088R
SkinBioTherapeutics PLC
24 August 2026
 

A blue text on a white background Description automatically generated 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Appointment of Interim CFO

 

24 August 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has appointed Anita Slater as Interim CFO (non-Board) for an initial six-month term. Ms Slater will start her duties with immediate effect to ensure an orderly handover with an interim finance team.

Anita Slater has 30 years' experience in commercial and financial senior leadership roles including Board positions, and has worked across start-ups, AIM-listed firms, and FTSE top 10 companies in energy, infrastructure, and manufacturing. She started her career at BG Group (now Shell) where she worked for c.19 years and rose to be Portfolio & Planning Manager for the Global Business Development team and finished her term there as the Shell-BG Merger Exploration Transition Team Manager, following Shell's acquisition. Having left the oil and gas sector in 2016, Anita worked in the renewable energy and technology sectors and was focused on formulating and delivering growth strategies. She worked in executive (including CFO) roles with a number of companies in this space, including, Tokamak Energy, AIM-listed AMTE Power plc, mining and renewable energy ventures Blue International Group and Joule Africa.

She qualified as a Chartered Accountant at PwC and is a fellow of the Institute of Chartered Accountants in England and Wales (ICAEW) and is a Business & Finance Professional (BFP). She has a BSc (Hons) in Applied Economics from the University of Plymouth.

Alyson Levett, Interim Chair of SkinBioTherapeutics, said:

"On behalf of the Board, I am delighted to welcome Anita to SkinBio as interim CFO. She brings extensive experience in financial and commercial leadership, together with strong expertise in governance, risk and financial controls. We have made significant progress in strengthening the Group's governance and financial framework, and Anita's experience will be invaluable as we build on that work and the ongoing focus on the commercial development of the business."

The Company is in advanced discussions with potential NED candidates and looks forward to updating the market in due course, and is also intending to issue a business update by mid-September which will include further Board updates.

 

-Ends-

Thumbnail image

Interim CFO, Anita Slater

Full image available upon request

 

For more information please contact:

SkinBioTherapeutics plc
Alyson Levett, Interim Chair
Rachel Parsonage, Interim CEO

ir@skinbiotix.com

 

Singer Capital Markets (Nominated Adviser & Broker)
Alex Bond
Sara Hale
Patrick Weaver

+44 (0) 020 7496 3000

 

Vigo Consulting
Melanie Toyne-Sewell
Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.

SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADXLFLQVLLBBV
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read